Emergent BioSolutions received a $30 million contract modification from BARDA to supply CYFENDUS® anthrax vaccine, deliveries planned through March 2026.
Quiver AI Summary
Emergent BioSolutions Inc. announced a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply its anthrax vaccine, CYFENDUS®, with deliveries expected to start this year and conclude by March 2026. This contract aims to enhance the availability of medical countermeasures against anthrax, a significant biological threat. Paul Williams from Emergent emphasized the importance of a U.S.-based supply chain in supporting national security. CYFENDUS® was approved for use in individuals aged 18 to 65 after potential exposure to anthrax and is intended for post-exposure prophylaxis alongside antibacterial treatment. This new contract follows a previous $50 million modification for the same vaccine in December 2024.
Potential Positives
- Emergent BioSolutions secured a significant $30 million contract modification from BARDA to supply the CYFENDUS® anthrax vaccine, indicating strong government support and confidence in the company's capabilities.
- The contract modification adds to a previous $50 million contract, highlighting the company's established relationship and ongoing collaboration with the U.S. government in national security efforts.
- CYFENDUS® was recently approved by the FDA for post-exposure prophylaxis, demonstrating Emergent's commitment to addressing public health threats and enhancing its product portfolio.
Potential Negatives
- The efficacy of the CYFENDUS® vaccine for post-exposure prophylaxis is based solely on studies in animal models, raising questions about its effectiveness in humans.
- There are significant safety concerns, including potential fetal harm and increased risk of birth defects when administered to pregnant individuals.
- The press release emphasizes the need for appropriate medical treatment to manage possible anaphylactic reactions, indicating inherent risks associated with the vaccine administration.
FAQ
What is the purpose of the $30 million contract modification?
The contract modification supports the supply of CYFENDUS® anthrax vaccine to safeguard against potential threats to public health.
When will deliveries of the CYFENDUS® vaccine begin?
Deliveries are expected to begin in the current calendar year and will be completed by March 2026.
What age group is CYFENDUS® approved for?
CYFENDUS® is approved for individuals aged 18 to 65 for post-exposure prophylaxis against anthrax.
What are the common side effects of the CYFENDUS® vaccine?
Common side effects include tenderness, pain, muscle aches, and tiredness, among others.
Where can adverse reactions be reported?
Adverse reactions can be reported to Emergent BioSolutions or through the Vaccine Adverse Event Reporting System (VAERS).
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EBS Insider Trading Activity
$EBS insiders have traded $EBS stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- NEAL FRANKLIN FOWLER sold 35,000 shares for an estimated $204,050
- KATHRYN C ZOON has made 0 purchases and 2 sales selling 17,086 shares for an estimated $120,152.
- DONALD W DEGOLYER sold 7,844 shares for an estimated $67,830
- KEITH KATKIN sold 7,844 shares for an estimated $49,417
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EBS Hedge Fund Activity
We have seen 95 institutional investors add shares of $EBS stock to their portfolio, and 99 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,525,313 shares (+137.6%) to their portfolio in Q2 2025, for an estimated $16,111,496
- OAK HILL ADVISORS LP added 2,500,000 shares (+224.5%) to their portfolio in Q2 2025, for an estimated $15,950,000
- MILLENNIUM MANAGEMENT LLC removed 1,747,056 shares (-69.8%) from their portfolio in Q2 2025, for an estimated $11,146,217
- QUBE RESEARCH & TECHNOLOGIES LTD removed 740,415 shares (-68.1%) from their portfolio in Q2 2025, for an estimated $4,723,847
- GEODE CAPITAL MANAGEMENT, LLC added 666,708 shares (+108.9%) to their portfolio in Q2 2025, for an estimated $4,253,597
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 605,576 shares (-71.3%) from their portfolio in Q2 2025, for an estimated $3,863,574
- PACER ADVISORS, INC. added 556,730 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,551,937
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EBS Analyst Ratings
Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/01/2025
To track analyst ratings and price targets for $EBS, check out Quiver Quantitative's $EBS forecast page.
Full Release
GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS ® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar year and are scheduled to be completed by March 2026.
"This new contract modification is the next step in our ongoing engagement with the U.S. government, with the shared goal to help ensure medical countermeasures, like CYFENDUS ® vaccine, are readily available to safeguard civilian populations against the potential threat of anthrax,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “We're proud to leverage a U.S.-based supply chain for our anthrax vaccines, as we believe this is critical to Emergent’s leadership and continued support of the U.S. government’s national security priorities.”
Anthrax is a Tier 1 biological threat due to its potential to be used for a bioterrorist incident and threat to public health and national security. CYFENDUS ® vaccine was approved by the U.S. Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age when given with recommended antibacterial drugs.
This follows a previously announced contract modification of $50 million to supply CYFENDUS ® (Anthrax Vaccine Adsorbed, Adjuvanted) in December 2024. This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract HHSO100201600030C.
About CYFENDUS ® (Anthrax Vaccine Adsorbed, Adjuvanted)
Indication
CYFENDUS ® (Anthrax Vaccine Absorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when given with recommended antibacterial drugs. The efficacy of CYFENDUS ® vaccine for post-exposure prophylaxis (PEP) is based solely on studies in animal models of inhalational anthrax.
Important Safety Information
Contraindication : Do not administer CYFENDUS ® to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) following a previous dose of CYFENDUS ® , BioThrax ® (a licensed anthrax vaccine with the same active ingredient as CYFENDUS ® ) or any component of the vaccine.
Warnings and Precautions : Management of Acute Allergic Reactions : Appropriate medical treatment must be available to manage possible anaphylactic reactions following administration of CYFENDUS ® . Pregnancy : CYFENDUS ® can cause fetal harm when administered to a pregnant individual. In an observational study, there were more birth defects in infants born to individuals vaccinated with BioThrax ® (a licensed anthrax vaccine with the same active ingredient as CYFENDUS ® ) in the first trimester compared to infants born to individuals vaccinated post pregnancy or individuals never vaccinated with BioThrax ® .
Adverse Reactions : The most common (≥10%) injection-site adverse reactions reported were tenderness, pain, arm motion limitation, warmth, induration, itching, swelling, and erythema/redness. The most common systemic adverse reactions were muscle aches, tiredness, and headache.
To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-800-768-2304 or [email protected] ; or VAERS at 1-800-822-7967 or www.vaers.hhs.gov .
Please see the Prescribing Information for CYFENDUS ® for full safety information.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our
website
and follow us on
LinkedIn
,
X
,
Instagram
,
Apple Podcasts
and
Spotify
.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the expected timing for delivery of the CYFENDUS
®
vaccine and Emergent’s ability to increase inventories of CYFENDUS
®
vaccine to meet requested levels within specified time frames, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
[email protected]
Media Contact:
Assal Hellmer
Vice President, Communications
[email protected]
